Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre

• Published in: International ophthalmology 2020-02, Vol.40 (2), p.377-383
• Main Authors: Kóthy, Péter, Holló, Gábor
• Format: Article
• Language: English
• Subjects: Adrenergic alpha-2 Receptor Agonists - administration & dosage; Aged; Brimonidine Tartrate - administration & dosage; Carbonic anhydrase; Carbonic Anhydrase Inhibitors - administration & dosage; Carbonic anhydrases; Drug Combinations; Eye (anatomy); Female; Glaucoma; Glaucoma, Open-Angle - drug therapy; Glaucoma, Open-Angle - physiopathology; Humans; Hypertension; Intraocular pressure; Intraocular Pressure - drug effects; Male; Medical records; Medicine; Medicine & Public Health; Ocular Hypertension - drug therapy; Ocular Hypertension - physiopathology; Ophthalmic Solutions; Ophthalmology; Original Paper; Pilocarpine; Reduction; Retrospective Studies; Sulfonamides - administration & dosage; Tertiary Care Centers; Therapy; Thiazines - administration & dosage; Timolol; Tonometry, Ocular
• ISSN: 0165-5701; 1573-2630
• DOI: 10.1007/s10792-019-01194-6

Purpose To investigate the intraocular pressure (IOP)-lowering efficacy and tolerance of brinzolamide/brimonidine fixed combination (BBFC) under real-life conditions in a tertiary glaucoma centre. Methods Medical records of all ocular hypertensive and open-angle glaucoma patients ( n  = 52) treated with BBFC were retrospectively analysed. Results Thirty-nine patients had primary open-angle, 6 exfoliative, 2 pigment, 1 normal tension and 1 juvenile open-angle glaucoma and 3 ocular hypertension. The prior therapy was a prostaglandin analogue (PG) ( n  = 4), PG/timolol ( n  = 20), PG/timolol and topical carbonic anhydrase inhibitor (CAI; n  = 19), timolol/CAI ( n  = 1), PG and CAI ( n  = 4), timolol/pilocarpine and PG ( n  = 1), timolol/brimonidine and PG ( n  = 1) and timolol/brimonidine, PG and CAI ( n  = 2). These were simplified to PG/timolol and BBFC ( n  = 41), PG and BBFC ( n  = 9), timolol and BBFC ( n  = 1) and timolol/pilocarpine, PG and BBFC ( n  = 1). The IOP on the study eyes was 21.2 ± 3.7 mmHg before and 16.9 ± 2.6, 16.0 ± 2.2, 17.6 ± 3.1 and 18.0 ± 3.1 mmHg after the introduction of BBFC at month 1, 3, 6 and 12, respectively ( p